Management and Evolution of Frontline Therapy in LAL Patients

The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today’s episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discussed by renowned experts during the EBMT-EHA 6th European CAR T-cell meeting.

In this podcast, André Baruchel, MD, PhD, Hospital Robert Debré AP-HP, Paris, France, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Alex Rampotas, MD, University College London, London, UK, cover several topics, including challenges with administering CAR-T therapy in B- and T-ALL, the possibility of exploring dual-targeting of CD19 and CD22 to overcome resistance, considerations for managing patients with B-ALL prior to CAR-T therapy, and more.

The post Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks appeared first on VJHemOnc.